Payment overview · 2025
General Payments
$1,453.80
16 reported records · 9 companies
Healthcare provider profile · identity verified
Edgardo Benavides, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1194919639
Verified facts
What the public records show
CMS Open Payments records show Edgardo Benavides, D.O. received $1,453.80 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $374.32 | 25.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $267.84 | 18.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.75 | 11.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $134.74 | 9.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.99 | 8.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $124.99 | 8.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $121.97 | 8.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $119.76 | 8.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.44 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,453.80 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $267.84 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $249.34 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $133.22 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $121.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $119.76 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $9.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 40 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 283 | 91 |
| Lisinopril | Lisinopril | 270 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 269 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 66 |
| Losartan Potassium | Losartan Potassium | 187 | 56 |
| Ozempic | Semaglutide | 185 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 54 |
| Omeprazole | Omeprazole | 168 | 54 |
| Gabapentin | Gabapentin | 149 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 54 |
| Metformin Hcl Er | Metformin Hcl | 118 | 45 |
| Montelukast Sodium | Montelukast Sodium | 112 | 38 |
| Metformin Hcl | Metformin Hcl | 109 | 36 |
| Carvedilol | Carvedilol | 105 | 30 |
| Tramadol Hcl | Tramadol Hcl | 101 | 26 |
| Alprazolam | Alprazolam | 96 | 17 |
| Famotidine | Famotidine | 90 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 26 |
| Mounjaro | Tirzepatide | 76 | 15 |
| Alendronate Sodium | Alendronate Sodium | 74 | 29 |
| Azithromycin | Azithromycin | 74 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 15 |
| Trazodone Hcl | Trazodone Hcl | 66 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 24 |
| Furosemide | Furosemide | 61 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 16 |
| Meloxicam | Meloxicam | 56 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 20 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 17 |
| Fluconazole | Fluconazole | 44 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 15 |
| Glipizide | Glipizide | 43 | suppressed |
| Jardiance | Empagliflozin | 43 | 15 |
| Eliquis | Apixaban | 40 | 13 |
| Finasteride | Finasteride | 39 | 12 |
| Ondansetron Odt | Ondansetron | 39 | 17 |
| Simvastatin | Simvastatin | 37 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 18 |
| Prednisone | Prednisone | 35 | 29 |
| Fenofibrate | Fenofibrate | 34 | 11 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 13 |
| Ibuprofen | Ibuprofen | 32 | 15 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | 12 |
| Farxiga | Dapagliflozin Propanediol | 30 | 11 |
| Methylprednisolone | Methylprednisolone | 30 | 20 |
| Spironolactone | Spironolactone | 30 | 13 |
| Buspirone Hcl | Buspirone Hcl | 29 | 11 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 15 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 13 |
| Topiramate | Topiramate | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Baclofen | Baclofen | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,453.80 · 16 records | Novo Nordisk Inc | AREXVY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ELIQUIS, Kerendia, Korlym, NURTEC ODT, Ozempic, QULIPTA, REPATHA, REXULTI, UBRELVY, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error